NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.180
+0.060 (5.36%)
Jan 22, 2025, 2:00 PM EST - Market open
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2024. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,350,316
Market Cap
16.93M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
NNVC News
- 9 days ago - NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 - Accesswire
- 14 days ago - Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals - Accesswire
- 4 weeks ago - NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape - Accesswire
- 2 months ago - NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID - Accesswire
- 2 months ago - NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - Accesswire
- 3 months ago - NanoViricides President Dr. Diwan to Present at the PODD Conference - Accesswire
- 3 months ago - NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology - Accesswire
- 3 months ago - NanoViricides to Present at the Global AMR Summit 2024 Tomorrow - Accesswire